Ankylosing spondylitis

NICE appraisal

TA143 Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis

DSU reports

Ankylosing spondylitis: a comparison of cost effectiveness models (PDF, 126KB) (May 2007)

Comparisons of submitted models for the appraisal of etanercept, adalimumab and infliximab for ankylosing spondylitis (PDF, 68KB) (February 2007)

Related publications

A Wailoo, N Bansback, J Chilcott. Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: reply Rheumatology 2008; Vol 47 (10): 1590

A Wailoo, N Bansback, J Chilcott. Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance Rheumatology 2008; Vol 47 (2): 119-120